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Abstract
Early dietary treatment of phenylketonuria (PKU), an inborn error of phenylalanine (Phe) metabolism, results in normal cognitive
development. Although health-related quality of life (HRQoL) of PKU patients has been reported as unaffected in high-income
countries, there are scarce data concerning HRQoL and adherence to treatment of PKU children and adolescents from Brazil.
The present study compared HRQoL scores in core dimensions of Brazilian early-treated PKU pediatric patients with those of
a reference population, and explored possible relationships between adherence to treatment and HRQoL. Early-treated PKU
pediatric patient HRQoL was evaluated by self- and parent-proxy reports of the Pediatric Quality of Life Inventory (PedsQL) core
scales. Adherence to treatment was evaluated by median Phe levels and percentage of results within the therapeutic target
range in two periods. Means for total and core scales scores of PedsQL self- and parent proxy-reports of PKU patients were
significantly lower than their respective means for controls. Adequacy of median Phe concentrations and the mean percentage
of values in the target range fell substantially from the first year of life to the last year of this study. There was no significant
difference in mean total and core scale scores for self- and parent proxy-reports between patients with adequate and those with
inadequate median Phe concentrations. The harmful consequences for intellectual capacity caused by poor adherence to
dietary treatment could explain the observed decrease in all HRQoL scales, especially in school functioning. Healthcare system
and financial difficulties may also have influenced negatively all HRQoL dimensions.
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Introduction
Phenylketonuria (PKU, OMIM 261600) is an autosomal
recessive inborn error of phenylalanine metabolism, caused
by a deficient activity of phenylalanine hydroxylase (PAH,
EC 1.14.16.1) – an enzyme that coverts the essential amino
acid phenylalanine (Phe) to tyrosine, leading to an accumu-
lation of Phe in blood and other tissues (1). When untreated,
most individuals with PKU develop severe intellectual dis-
ability, microcephaly, neurological disorders, eczema and
decreased hair and skin pigmentation (2). In Latin America,
it was estimated an incidence of PKU of about 1:21,000
live births (1:12,000 to 1:52,000) (3). In Brazil, the incidence
of PKU was reported as approximately 1 in 25,000 live
births (4), although there are important variations among dif-
ferent Brazilian states, from 1:9,000 to 1:33,000 (5–9).
The establishment of mass newborn screening programs
allowed the detection of PKU in the neonatal period and the
early establishment of dietary treatment, resulting in a normal
cognitive development (10). In 2001, the National Neonatal
Screening Program was established within the Brazilian
National Health System, ensuring access of all newborns to
screening, confirmatory tests, and treatment for PKU, includ-
ing the provision of metabolic phenylalanine-free formula (4).
The need to adhere to a strict diet, frequent blood
sampling to monitor the levels of Phe and regular visits to
health services, can affect daily life and therefore have a
negative impact on the health-related quality of life (HRQoL)
of individuals affected by PKU (11–13). In addition, there is
evidence that adherence to diet treatment in early-treated
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PKU patients deteriorates with increasing age, being
unsatisfactory in older children and adolescents (14).
Low adherence to treatment, besides its negative conse-
quences for the psychomotor development of pediatric
patients, could also reduce their HRQoL, as has been
suggested for adults (15,16).
The present study intends to contribute to the knowl-
edge of HRQoL of early-treated pediatric patients in Brazil,
investigating differences in core dimensions of this out-
come measure between them and a reference healthy
schoolchildren population, and exploring possible relation-
ships between adherence to treatment and HRQoL.
Material and Methods
Study design
The study was conducted from March 2012 to July
2014. Parents of patients with early-treated PKU, rang-
ing in age from 6 to 18 years, followed in two centers
in Brazil – State Institute of Diabetes and Endocrinology
Luiz Capriglione (IEDE), Rio de Janeiro, RJ, and Medical
Genetics Service, Hospital de Clínicas de Porto Alegre
(HCPA), Porto Alegre, RS, were invited to participate
in the study. The affected individuals should have had a
diagnosis of classic, moderate or mild PKU in the first four
months of life, and since then been submitted to a protein-
restricted diet supplemented with a Phe-free amino acid
formula. Classic PKU was defined as the finding of pre-
treatment blood Phe levels repeatedly 41200 mmol/L
(420 mg/dL), whereas moderate and mild PKU were
characterized by pre-treatment blood Phe levels in the
ranges of 900–1200 mmol/L (15–20 mg/dL), and 600–
900 mmol/L (10–15 mg/dL), respectively (17). They might
have presented varying degrees of treatment adherence
and metabolic control, but all participants had their blood
Phe levels regularly monitored.
The following exclusion criteria were adopted: 1) inability
of children and parents in understanding the study ques-
tionnaires; 2) presence of severe chronic or disabling
diseases unrelated to PKU.
Participants’ demographics
A total of 105 affected pediatric patients fulfilled the
eligibility criteria, of which 63 were followed at IEDE and
42 at HCPA. Fifty-one of the 105 eligible children and
adolescents with PKU were recruited and accepted to
participate in the study (response rate 49%), including 38
followed at IEDE and 13 at HCPA. The sample included
33 classic PKU and 17 mild or moderate PKU patients
(for 1 patient this information could not be obtained). The
mean age at diagnosis was 45±22 days, and the mean
age at the start of treatment with a Phe-restricted diet was
48±20 days.
Thirteen of 38 children and adolescents from Rio
de Janeiro evaluated by RCPM and RSPM had their
intellectual capacity classified as Grade IV (definitely
below average in intellectual capacity) or Grade V (intel-
lectually defective). Intellectual capacity of 1 of 13 patients
from Rio Grande do Sul was evaluated clinically as
defective with no formal psychometric test being applied.
Twenty-nine patients lived in Metropolitan areas, while
22 lived in the countryside of both states. Twenty-two
females and 29 males were enrolled in the study. Twenty-
five children and adolescents belonged to middle-income
families (class C), 20 to high-income families (classes A
and B), and 2 to low-income families (class D) – four families
did not fill the socioeconomic status evaluation form.
The gender distribution of our sample of patients did
not differ from that of the normative sample of healthy
school children and adolescents (21) (w2=1.2240, P=0.269).
The socioeconomic status distribution of our sample of
patients differed from the normative sample (w2=6.7518,
P=0.034), due to the higher percentage of high-income
families in our sample – 42.6 vs 31.1%. Nevertheless, the
socioeconomic status distribution of our PKU patient sample
did not differ significantly from those of the populations of
Rio de Janeiro (w2=7.6612, P=0.176) and Porto Alegre
(w2=2.5856, P=0.764) metropolitan areas (22).
Ethical issues
This study was approved by the Research Ethics
Review Committee of IEDE and HCPA. At all times, the
study was conducted under ethical principles and in line
with the Guidelines and Standards for Research in Human
Beings, established by Resolution No. 466/2012 of the
Brazilian National Health Council (18). Informed consent
was obtained from the parents or guardians of all pediatric
patients engaged in this study. Active consent was then
obtained from each individual child and adolescent whose
parents agreed to his/her participation.
Quality of life and socioeconomic status
questionnaires, and intellectual capacity tests
Pediatric Quality of Life Inventory (PedsQL) Version
4.0 is a generic questionnaire for assessing HRQoL of
children and adolescents aged 2 to 18 years, originally
developed by Varni et al. (19). Its core scales are designed
to evaluate four dimensions – physical health, emotional
functioning, social functioning, and school functioning.
The aggregation of emotional, social and school dimen-
sions is the psychosocial health summary score (19).
Items of the questionnaire are Likert scales that are
reverse-scored and linearly transformed to a 0–100 scale,
where higher scores represent better quality of life. Self-
assessment and parent proxy forms of the questionnaire
were employed according to the child or adolescent’s age.
Normative data from healthy children and adolescents
were collected in the city of São Paulo, SP, Brazil, by
the authors of the translation and validation to Brazilian
Portuguese of the original English version of PedsQL 4.0,
which results have been published elsewhere (20,21).
This reference population included 240 healthy children
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and adolescents from 2 to 18 years of age living in urban
areas of the outskirts of Greater São Paulo, and their respec-
tive parents. Enrolment locations were public schools for
children aged 5 to 18 and primary healthcare units for
children aged 2 to 4. Inclusion criteria included ability to
answer the HRQoL questionnaire, absence of chronic or
acute illness in the last 30 days before the interview, and
presence of at least 1 parent on the day the questionnaire
was applied.
Socioeconomic status evaluation of the families of chil-
dren and adolescents with PKU was carried out according
to the criteria of the Brazilian Association of Research
Companies (22). For comparison purposes, these criteria
were simplified to three classes: low-income (classes D
and E), middle-income (classes C1 and C2), and high-
income classes (classes A1, A2, B1, and B2).
Intellectual capacity of children aged 6 to 11 years was
evaluated by Raven’s Colored Progressive Matrices -
RCPM (23), and of adolescents aged 12 to 18 years by
Raven’s Standard Progressive Matrices - RSPM (24).
These are non-verbal intelligence tests developed by
John C. Raven in 1936 in the United Kingdom, which
employ abstract geometrical figures to directly measure
general intelligence, and avoid influences of cultural
elements and training. In the present study, we used the
Brazilian standardizations of RCPM and of RSPM. The
Brazilian standardization of RCPM is based on the results
of 1547 kindergarten and elementary school children,
aged 5 to 11.5 years, from the city of São Paulo (25), and
of RSPM is based on 366 individuals with educational
level ranging from elementary to postgraduate school,
from the city of Rio de Janeiro (24).
Adherence to treatment
Adherence to treatment was measured indirectly by
the median Phe level in the first year of life and in the last
year of treatment evaluated by this study (2010–2012).
We also evaluated, for both periods, the percentage of
blood Phe results in the treatment target range according
to the Brazilian PKU Guidelines (26). Adherent children
and adolescents were defined as those with median Phe
levels p6 mg/dL in the first year of life, or p10 mg/dL for
those X13 years of age and p6 mg/dL for those o13,
in the last year of the study.
Statistical analyses
The t-test for two independent samples was conducted
between the normative pediatric data and the results of
the self-assessment and parent proxy reports for the
PedsQL core scales of PKU children and adolescents in
this study. This same test was employed to evaluate
potential significant differences in HRQoL between states
or area of residence (Rio de Janeiro and Porto Alegre
Metropolitan areas or countryside), gender, and severity
of disease (classic or mild PKU). One-way ANOVA was
used to assess differences in HRQoL scores due to
socioeconomic status. A multi-way ANOVA taking into
account state or area of residence, gender, disease
severity, and socioeconomic status was also performed.
Associations between scales of the PedsQL dimen-
sions for self-assessment and parent proxy reports and
the adherence to treatment variables were examined
by linear regression analysis. Two independent samples
t-test was conducted between the results of the self-
assessment and parent proxy reports of the PedsQL
scales for adherent and non-adherent PKU children and
adolescents. A multi-way ANOVA taking into account
adherence to treatment in the first year of life and in the
last year of the study and the other previously mentioned
independent variables was also carried out.
All statistical analyses were conducted with Stata/SE
12.1 for Mac software package (StataCorp, USA).
Minimum sample size
The minimum sample size was calculated from the
previously published mean scores and standard devia-
tions for the PedsQL core scales results of the self-
assessment and parent proxy reports of Brazilian healthy
children and children with rheumatic diseases (20). A min-
imum sample size of 35 children in each group was
considered in order to detect a difference of ten points
on a hypothetical scale, the variance of which was the
mean of the weighted variances of the physical, emotional,
social and school scales of the self-assessment and
parent proxy reports (219.5), accepting an alpha error of
5% and a beta error of 20%.
Results
HRQoL
PedsQL self-reports were administered to 49 early-
treated PKU patients aged 6 to 17 years – self-reports
could not be administered to 2 patients (1 refused to
answer the questionnaire and the other was not able to
fill it out owing to intellectual disability). Means for total
score and for the scores from physical health, emotional
functioning, social functioning, school functioning, and
psychosocial health scales for PedsQL self-reports were
significantly lower than the respective means from the
normative sample of healthy schoolchildren (Table 1).
In addition, PedsQL parent proxy-reports were admi-
nistered to 34 parents and caretakers of early-treated PKU
children and adolescents. Most of these parents and
caretakers (33) were from Rio de Janeiro, which corre-
sponds to 86.8% of this state sample. With the exception
of emotional functioning scale, mean scores for the generic
core scales for parent proxy-reports were significantly lower
than the respective means for parent proxy-reports from the
normative sample (Table 2).
The mean total score for PedsQL self-reports of children
and adolescents from Rio de Janeiro (n=37) was not
significantly different from the mean of their peers from
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Rio Grande do Sul (n=12, t=0.5911, P=0.5573). We did
not find significant differences between pediatric patients
from the two states with regard to emotional functioning
(t=0.4868, P=0.6287), social functioning (t=–0.7870,
P=0.4352), school functioning (t=–0.6960, P=0.4899),
and psychosocial health (t=–0.4910, P=0.6257) scores.
Unexpectedly, the patients from Rio de Janeiro evaluated
their physical health more positively than their peers from
Rio Grande do Sul (t=2.3615, P=0.0224). This difference
was upheld even when other independent variables such
as region, gender, socioeconomic class, and disease
severity were taken into account in a multi-way ANOVA
model (F=11.85, P=0.0014). The number of parent proxy-
reports from Rio Grande do Sul (n=1) was too small to
allow any statistical inference.
In addition, children and adolescents from the interior
of both states (n=22) evaluated their global quality of
life similar to those living in the metropolitan areas (n=29)
(t=–0.8086, P=0.4228). Mean scores for all the generic
self-report core scales did not differ significantly between
countryside and metropolitan area pediatric patients.
Parent proxy-reports from Rio de Janeiro pediatric
patients also did not show any significant difference
between metropolitan area (n=23) and countryside (n=10)
concerning PedsQL total score (t=–0.6348, P=0.5302).
Mean scores for all the generic parent proxy-report core
scales did not differ significantly between patients from
countryside and metropolitan areas of Rio de Janeiro.
We did not find any significant gender difference con-
cerning the self-perception (t=–1.3172, P=0.1942) and
the parents’ perception (t=–0.8625, P=0.3948) of quality
of life assessed by PedsQL self-report and parent proxy-
report total scores. But girls self-evaluated their emotional
functioning more negatively than boys (t=–2.8485, P=0.0065).
This was the only PedsQL core scale that showed any
gender difference for self-reports, but this difference
tended to disappear when other independent variables
were included in a multi-way ANOVA model (F=3.06,
P=0.0884). Considering exclusively parent proxy-reports,
there was no gender difference in any PedsQL core scale.
Mean total score for PedsQL self-reports of children
and adolescents with mild or moderate PKU was not sig-
nificantly different compared to pediatric patients affected
by classic PKU (t=–0.1901, P=0.8501). Physical health
(t=–0.2400, P=0.8114), emotional functioning (t=0.6868,
P=0.4957), social functioning (t=–0.5163, P=0.6081),
school functioning (t=–0.3594, P=0.7210), and psycho-
social health (t=–0.1240, P=0.9019) self-report scores did
not show any significant difference between mild or
moderate and classic PKU pediatric patients either.
Nevertheless, the mean total score for PedsQL parent-
reports of children and adolescents with mild or moderate
Table 1. Self-reported scores for PedsQL 4.0 generic core scales of Brazilian early-treated phenylketonuria
(PKU) pediatric patients.
Aspect Items PKU (n=49) Controls (n=180) P
Total score 23 75.31±12.04 88.90±7.35 o0.0001
Physical health 8 82.54±14.67 95.94±5.83 o0.0001
Emotional functioning 5 66.84±18.31 73.03±16.52 0.0241
Social functioning 5 79.29±22.52 93.14±10.54 0.0001
School functioning 5 68.27±17.00 89.31±11.80a o0.0001
Psychosocial health 15 71.44±13.73 85.03±9.66 o0.0001
Data are reported as means±SD. The t-test for two independent samples considering as controls a group
of healthy school children of the city of São Paulo, Brazil was used. a n=173.
Table 2. Parent-proxy scores for PedsQL 4.0 generic core scales of Brazilian early-treated phenylketonuria
(PKU) pediatric patients.
Aspect Items PKU (n=34) Controls n=240) P
Total score 23 79.98±16.26 92.32±6.01 0.0001
Physical health 8 89.62±16.71 97.86±4.31 0.0072
Emotional functioning 5 73.97±20.59 80.52±12.59 0.0789a
Social functioning 5 84.85±21.93 96.38±8.89 0.0046
School functioning 5 65.74±24.25 90.93±11.85b o0.0001
Psychosocial health 15 74.85±18.24 89.18±8.19 0.0001
Data are reported as means±SD. The t-test for two independent samples considering as controls a group
of healthy school children of the city of São Paulo, Brazil was used. a Non-significant difference. b n=207.
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PKU was significantly higher than that of parent-reports of
pediatric patients affected by classic PKU (t=–2.5012,
P=0.0189). This difference tended to disappear when
other independent variables (region, socioeconomic class,
and disease severity) were included in a multi-way ANOVA
model (F=3.97, P=0.0561). Similar differences were also
found concerning physical health (t=–2.2383, P=0.0323),
and school functioning (t=–2.0841, P=0.0452) in parent-
report scores. However, only mean score for school func-
tioning in parent-reports was persistently lower in classic
PKU (62.2) than mild or moderate PKU (80.6) in a multi-
way ANOVA model (F=4.42, P=0.0446). No significant
differences were found between the two groups with
regard to emotional functioning (t=–1.2524, P=0.2195),
social functioning (t=–1.0938, P=0.2838), and psycho-
social health (t=–1.6988, P=0.0991) scores.
The number of low-income class families of PKU
patients (classes D and E, n=2) was too small for making
any significant conclusions. Thus, the assertions regard-
ing socioeconomic classes refer to differences between
middle-income – C (n=24) and high-income – A and B
(n=20) classes. There was no significant difference in
mean total score for PedsQL self-reports of children and
adolescents among different socioeconomic classes
(F=0.68, P=0.5113). Physical health (F=0.20, P=0.8199),
social functioning (F=0.18, P=0.8367), school functioning
(F=0.93, P=0.4014), and psychosocial health (F=0.79,
P=0.4596) self-report scores also did not show any
significant difference among socioeconomic classes, but
surprisingly children and adolescents from middle-income
class evaluated their emotional functioning more positively
than their high-income class peers (F=6.60, P=0.0032).
This difference was retained even when other indepen-
dent variables were considered in a multi-way ANOVA
model (F=11.29, P=0.0018).
With reference to the parent proxy-reports, we also did
not find a significant difference in mean total score among
different socioeconomic classes (t=0.5448, P=0.5898).
Physical health (t=0.6749, P=0.5070), emotional function-
ing (t=–0.0050, P=0.9960), social functioning (t=0.3839,
P=0.7037), school functioning (t=0.6228, P=0.5379), and
psychosocial health (t=0.4210, P=0.6767) parent proxy-
report scores also did not show any significant difference
among socioeconomic classes.
Adherence to treatment
The mean value for the median Phe concentration
in the first year of life was 5.3±4.1 mg/dL. Thirty-five
children (70.0%) had adequate median Phe concentra-
tions at this age, i.e., below the upper limit of the target
range for children 0 to 12 months of age – 2 to 6 mg/dL,
according to the Brazilian PKU Guidelines (26). The
distribution of the median Phe concentrations in the first
year of life is depicted in Figure 1. The mean percentage
of values in the target range was 61.3±28.9% in this
period. There was no significant difference in median Phe
concentrations in the first year of life among pediatric
patients of the two states (t=–0.6663, P=0.5087) or of
the two regions – countryside and metropolitan areas
(t=1.4452, P=0.1549) included in the present study.
Gender (t=0.0888, P=0.9296) and severity of disease
(t=1.0046, P=0.3203) also did not influence this adher-
ence parameter. The median Phe concentrations in the
first year of life of middle-income class patients did not
differ significantly from those of high-income class patients
(t=–0.3114, P=0.7571). Similar results were found for
the other parameter of adherence in the first year of life
(percentage of values in the target range).
In the last year of treatment evaluated by this
study (2010–2012) the mean value for the median Phe
Figure 1. Median phenylalanine levels in the
first year of life of Brazilian early-treated PKU
pediatric patients. Thirty percent of the patients
had median phenylalanine levels in the first year
of life above the upper limit of the recommended
target range for this age (6 mg/dL). PKU: phenyl-
ketonuria.
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concentration increased to 9.2±4.3 mg/dL, and the per-
centage of children with adequate median Phe concentra-
tions fell to 31.4% (16/51). The mean percentage of values
in the target range also dropped to 30.9±36.7% in the
last year of treatment. There was no significant difference
in median Phe concentrations in the last year of treatment
among pediatric patients of the two states (t=0.4737,
P=0.6378) or of the countryside and metropolitan areas
(t=–0.8735, P=0.3867) included in the present study.
Gender (t=0.4941, P=0.6235), disease severity (t=1.9745,
P=0.0541), and socioeconomic status (t=0.4676, P=0.6424)
also did not influence this adherence parameter. Similar
results were found for percentage of values in the target
range.
No statistically significant association was found between
scores for self-report PedsQL generic core scales and the
four ‘adherence to treatment’ variables by linear regres-
sion analysis (Table 3).
There was a significant inverse relationship between
parent proxy-report school functioning score and median
Phe levels in the first year of life (t=–2.64, P=0.013; Figure 2).
No other statistically significant association was found
between scores for parent proxy-report PedsQL generic
core scales and the four ‘adherence to treatment’ vari-
ables by linear regression analysis (Table 4)
Means for all self-report and parent proxy-report
scores of PedsQL generic core scales of adherent PKU
children and adolescents were not different from the
respective means of their non-adherent peers, both in
the first year of life and in the last year of the study
(Supplementary Table S1). A multi-way ANOVA taking into
account adherence to treatment in these two periods and
the other previously mentioned independent variables did
not show any significant difference attributable to adher-
ence for the self-report and parent proxy-report PedsQL
generic core scales score of adherent and non-adherent
PKU pediatric patients (Supplementary Table S2).
Discussion
A generic instrument of pediatric HRQoL, PedsQL,
was chosen to ascertain the impact of PKU and its treat-
ment on the daily life of affected individuals, in their phys-
ical, emotional, social, and school dimensions, allowing
the cross-comparison to a normal healthy population of
school-age children. Generic instruments of HRQoL permit
comparisons between different populations (27), and con-
sequently are indispensable for exploratory studies as
ours. Disease-specific instruments of HRQoL are gener-
ally more sensitive than generic versions for assessing
the impact of particular interventions, and are essential
to demonstrate small changes over time in HRQoL, for
example after the start of BH4 treatment (27,28). None-
theless, Brazilian and European Portuguese versions of
the PKU-specific HRQoL questionnaire, PKUQOL (28,29),
were not available during the execution of this study.
Lower scores were obtained for almost all the generic
core scales for PedsQL self-reports and parent-proxy
reports of PKU children and adolescents when compared
to a normative sample of healthy Brazilian schoolchildren.
This definitely is in contrast to the findings of most studies
done in high-income countries that demonstrated that
HRQoL of patients with PKU is similar to that of the general
population (11,12,28,30,31). PedsQL was employed only in
one of these studies (28), a recent multicenter European
study that showed that HRQoL scores of children,
adolescents, and adults with PKU evaluated by generic
instruments were in the same range as those established
as reference values for the US population.
This striking difference between our findings and those of
the studies from high-income countries could be attributed,
in the case of the European multicenter study (28), to the
access to pharmacological treatment with BH4, as increased
Phe tolerance and reduced metabolic formula require-
ment in BH4-responsive patients can improve HRQoL (32).
Table 3. Linear regression analysis of the self-report scores for PedsQL 4.0 generic core scales and adherence to treat-
ment variables of Brazilian early-treated phenylketonuria (PKU) pediatric patients.
Independent adherence to treatment variables
Aspect (dependent variable) Median Phe
1st year
% Phe results in the
target range 1st year
Median Phe
last year
% Phe results in the
target range last year
ta P t P t P t P
Total score –0.93 0.356 –0.14 0.891 –0.70 0.488 0.33 0.747
Physical health –1.28 0.208 1.67 0.102 –0.45 0.653 0.30 0.766
Emotional functioning 0.34 0.733 –1.45 0.154 0.21 0.831 –0.21 0.832
Social functioning –0.41 0.685 –0.60 0.550 –0.91 0.365 0.29 0.776
School functioning –1.19 0.242 –0.42 0.678 –0.66 0.512 0.49 0.630
Psychosocial health –0.53 0.599 –1.13 0.264 –0.68 0.501 0.27 0.791
Phe: phenylalanine. a t-statistic.
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Nevertheless, this cannot be sustained as the other four
studies were conducted before BH4 became available.
Difficulties faced by the Brazilian National Health System
in ensuring a regular supply of PKU metabolic formula to
patients, and the financial burden of out-of-pocket acquisi-
tion of low protein food by families may have a negative
impact on HRQoL of Brazilian PKU patients (33).
The relatively low response rate of the present study -
49%, compared to the studies of PKU patients in European
countries, ranging from 59 to 91% (11,12,28,30,31), could
not explain the lower HRQoL of Brazilian PKU children
and adolescents, since the included patients were those
that regularly attended the scheduled metabolic and nutri-
tional consultations, and therefore had presumably a
higher HRQoL than their counterparts that were dropping
out of follow-up.
Although our sample size was larger (self-assessment
form) or at the limit (parent proxy form) of the calculated
minimum number, the low response rate may have affected
the clinical strength of our results. Therefore, extrapolation
of our results to a national perspective ought to be made
with caution. A Brazilian multi-center study with a larger
cohort is necessary to achieve a stronger statistical and
especially clinical significance.
Two studies showed results similar to ours. One study
conducted in the Russian Federation, using the same
questionnaire as in the present study, showed statistically
significant lower scores for PKU children when compared
to healthy peers in all PedsQL core scales (34). Lower
HRQoL scores, assessed by the Child Health Question-
naire (CHQ), were also demonstrated in a group of
children and adolescents in Italy (35).
Figure 2. Parent proxy-report school functioning
score and median phenylalanine (Phe) levels in
the first year of life. A significant inverse relation-
ship between these two variables was found by
linear regression analysis (t=–2.64, P=0.013).
Table 4. Linear regression analysis of the parent proxy-report scores for PedsQL 4.0 generic core scales and adherence to
treatment variables of Brazilian early-treated phenylketonuria (PKU) pediatric patients.
Independent adherence to treatment variables
Aspect (dependent variable) Median Phe
1st year
% Phe results in the
target range 1st year
Median Phe
last year
% Phe results in the
target range last year
ta P t P t P t P
Total score –1.31 0.200 0.49 0.630 –0.42 0.679 –0.48 0.632
Physical health –0.83 0.415 0.50 0.617 –0.53 0.598 –0.40 0.689
Emotional functioning –0.71 0.484 –0.53 0.603 0.20 0.844 –0.51 0.616
Social functioning –0.17 0.869 –0.15 0.878 0.56 0.579 –1.55 0.130
School functioning –2.64 0.013* 1.64 0.111 –1.41 0.169 0.74 0.465
Psychosocial health –1.39 0.175 0.42 0.676 –0.31 0.760 –0.47 0.643
Phe: phenylalanine. a t-statistic. * Pp0.05.
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An increasingly low adherence to treatment over time
as PKU patients reached school age and particularly
adolescence was found in this study. This deterioration in
treatment adherence is expected in PKU patients as well
as in other chronic conditions that require diet therapy for
many reasons. Adolescents and adults perceive dietary
therapy as a constraint to their activities of daily living, find
it hard to prepare protein substitutes, are more prone to
social and peer group pressures, and may perceive their
condition as stable (14,31,36).
This non-adherence could have influenced negatively
HRQoL by reducing the intellectual capacity of PKU chil-
dren and adolescents. We could not demonstrate, on the
other hand, a correlation between adherence to treatment
and quality of life in these patients. The lower scores
obtained for almost all HRQoL scales by PKU children and
adolescents in comparison to a normative population could
not be attributed to non-adherence in the present study.
This absence of correlation between adherence to treat-
ment and HRQoL in PKU was also found by Cotugno et al.
(35) in Italy. Cazzorla et al. (37), also from Italy, reached
opposing results, finding an association between Phe
levels and HRQoL scores in PKU. However, they included
patients on BH4 treatment, and consequently their results
are not comparable to our and Cotugno et al. (35) studies.
There is a scarcity of studies addressing the correla-
tion between adherence to treatment and HRQoL in PKU
children and adolescents. These two Italian studies are
the few that directly concentrated on the subject.
Even though the correlation between compliance
and HRQoL in PKU is debatable, there is solid evidence
that PKU diet is hard to comply with (14,38), and, as a
result, patients and their families consider it as a limitation
to their daily life activities. This may have obscured any
potential difference attributable to adherence, and may
possibly have negatively influenced all HRQoL dimen-
sions independently of achieving recommended phenyla-
lanine levels.
Nevertheless, the importance of an adequate adher-
ence to treatment at an early age on cognitive develop-
ment and school performance cannot be overemphasized.
The lower performance of Brazilian PKU children in
executive functions (39), and intellectual capacity (40)
are most probably due to the highly unsatisfactory
adherence to diet treatment found in the reference centers
around the country. The significant inverse relationship
between parent proxy-report school functioning score
and median Phe levels in the first year of life found in
the present study (Figure 2) is a strong evidence of the
impact of non-adherence in cognitive performance.
Lower scores were obtained for almost all HRQoL
scales for self-reports and parent-proxy reports of PKU
patients when compared to a normative sample of healthy
Brazilian school children. Poor adherence to dietary treat-
ment, ascertained by phenylalanine blood levels, was also
found not to be optimal in the first year of life and tended
to worsen, as patients grew older. Nonetheless, no sig-
nificant differences in HRQoL scores were found between
adherent and non-adherent children and adolescents.
Failure of the healthcare system to ensure a regular
supply of PKU metabolic formula to patients and the
financial burden of acquisition of low protein food by
families can be compounded by the well-known barriers
to dietary compliance in PKU children and adolescents
from Brazil affecting negatively all HRQoL dimensions
irrespective of maintaining a satisfactory phenylalanine
blood level. Few articles have addressed the impact of
adherence to dietary treatment on HRQoL of patients
with PKU and consequently further studies are urgently
needed to clarify if adherence to diet therapy leads in
fact to a better HRQoL, especially among children and
adolescents.
Supplementary material
Click here to view [pdf].
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